Joseph Schwartz
Stock Analyst at Leerink Partners
(3.29)
# 1,009
Out of 5,065 analysts
151
Total ratings
33.58%
Success rate
21.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Outperform | $68 → $60 | $27.81 | +115.75% | 3 | Nov 10, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Outperform | $115 | $91.56 | +25.60% | 1 | Nov 10, 2025 | |
| RNA Avidity Biosciences | Downgrades: Market Perform | $65 → $72 | $70.56 | +2.04% | 4 | Oct 27, 2025 | |
| SPRB Spruce Biosciences | Maintains: Market Perform | $10 → $160 | $105.00 | +52.38% | 6 | Oct 21, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $80 → $88 | $42.84 | +105.42% | 2 | Sep 29, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Market Perform | $12 → $15 | $17.69 | -15.21% | 14 | Sep 9, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Outperform | $18 → $20 | $13.08 | +52.91% | 6 | Jul 7, 2025 | |
| INSM Insmed | Maintains: Outperform | $100 → $115 | $198.76 | -42.14% | 4 | Jun 10, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Outperform | $4 → $12 | $11.29 | +6.29% | 4 | May 23, 2025 | |
| MAZE Maze Therapeutics | Initiates: Outperform | $28 | $36.26 | -22.78% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $40 | $34.69 | +15.31% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $14 | $0.26 | +5,311.67% | 2 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.09 | - | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $4.70 | +155.32% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $1.80 | +344.44% | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $1 | $1.61 | -37.89% | 4 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $6 | $8.35 | -28.14% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $78.47 | -38.83% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $24.83 | -27.51% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $76.09 | -55.32% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $122 → $130 | $54.69 | +137.70% | 10 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $210.49 | -22.56% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.06 | +226.80% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $5.56 | +493.53% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $12 | $15.68 | -23.47% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $33.59 | +221.52% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $4 | $1.18 | +238.98% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $22.67 | +32.33% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $85.40 | -64.87% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $9.56 | +46.44% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $2.06 | +482.52% | 2 | Sep 26, 2017 |
uniQure
Nov 10, 2025
Maintains: Outperform
Price Target: $68 → $60
Current: $27.81
Upside: +115.75%
Monopar Therapeutics
Nov 10, 2025
Initiates: Outperform
Price Target: $115
Current: $91.56
Upside: +25.60%
Avidity Biosciences
Oct 27, 2025
Downgrades: Market Perform
Price Target: $65 → $72
Current: $70.56
Upside: +2.04%
Spruce Biosciences
Oct 21, 2025
Maintains: Market Perform
Price Target: $10 → $160
Current: $105.00
Upside: +52.38%
Crinetics Pharmaceuticals
Sep 29, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $42.84
Upside: +105.42%
Sarepta Therapeutics
Sep 9, 2025
Maintains: Market Perform
Price Target: $12 → $15
Current: $17.69
Upside: -15.21%
KalVista Pharmaceuticals
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $13.08
Upside: +52.91%
Insmed
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $198.76
Upside: -42.14%
Fulcrum Therapeutics
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $11.29
Upside: +6.29%
Maze Therapeutics
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $36.26
Upside: -22.78%
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $34.69
Upside: +15.31%
Sep 19, 2024
Maintains: Outperform
Price Target: $11 → $14
Current: $0.26
Upside: +5,311.67%
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.09
Upside: -
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $4.70
Upside: +155.32%
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $1.80
Upside: +344.44%
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.61
Upside: -37.89%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $8.35
Upside: -28.14%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $78.47
Upside: -38.83%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $24.83
Upside: -27.51%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $76.09
Upside: -55.32%
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $54.69
Upside: +137.70%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $210.49
Upside: -22.56%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.06
Upside: +226.80%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $5.56
Upside: +493.53%
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $15.68
Upside: -23.47%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $33.59
Upside: +221.52%
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $1.18
Upside: +238.98%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $22.67
Upside: +32.33%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $85.40
Upside: -64.87%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $9.56
Upside: +46.44%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $2.06
Upside: +482.52%